Tardive dyskinesia treatment with VMAT2 inhibitors — the vesicular monoamine transporter 2 blockade for drug-induced involuntary movement suppression representing the fastest-growing indication in the global VMAT2 inhibitor market — creates the most clinically significant market segment, with the VMAT2 Inhibitor Market reflecting tardive dyskinesia as the premium volume commercial...